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Endotheliuma b s t r a c t
Introduction: Endocan-1 has been proposed as a possible biomarker and predictor of vascular endothelial
related pathologies. Thus, we hypothesised that Endocan-1 levels would be up-regulated in maternal
plasma and placentae from women with pre-eclampsia. The aim of our study was to compare
Endocan-1 concentrations in maternal/fetal plasma and placentae from normotensive and pre-eclamptic
pregnancies.
Methods: Observational and case-controlled study, at the São Lucas Hospital, Brazil. Placental biopsies,
maternal/umbilical venous (fetal) plasma were taken from 67 normotensive and 50 pre-eclamptic
women. Endocan-1 levels were quantiﬁed using MagPlexTH-C and analysed by Analysis of Covariance
and Pearson correlation. The null hypothesis was rejected at p < 0.05.
Results: Higher levels of Endocan-1 were found in maternal plasma in the pre-eclamptic group (mean
ratio = 1.49; 95% conﬁdence interval: 1.19–1.85, p = 0.001), with a moderate effect size (Cohen’s
D = 0.84). Placental Endocan-1 levels (lg/g) were lower in pre-eclampsia (1.52 [1.10, 2.40] vs. 2.24
[1.32, 3.75], p = 0.033) and fetal Endocan-1 concentration (ng/ml) did not show any difference between
groups (3.10 [2.60, 4.54] vs. 2.91 [2.20, 3.66] p = 0.085). In addition, an up-regulation of maternal plasma
Endocan-1 in the pre-eclamptic group was observed when stratiﬁed in relation to gestational age, systolic
blood pressure and proteinuria (p < 0.05, for all). Furthermore, a positive correlation between Endocan-1
concentration in maternal vs. fetal plasma was also found (r = 0.258, p = 0.015). For the matched samples,
a negative correlation between Endocan-1 in maternal/fetal plasma with birthweights, placental weights
and gestational age at delivery was observed (p < 0.05 for all).
Discussion: Endocan-1 is increased in women with pre-eclampsia for all strata, which highlight the
importance of this molecule as a possible biomarker. The negative correlations between Endocan-1
and clinical data suggest that this molecule may also be involved with prematurity and low birth weight,
which warrants further investigations.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
Pre-eclampsia (PE) affects 2–8% of all pregnancies.
Characterised by de novo hypertension and proteinuria, it is
one of the leading causes of maternal and fetal mortality and
morbidity, worldwide [1]. It is thought to be initiated by poor pla-
centation, where impairment in vascular remodelling of uterine
spiral arteries leads to a decrease in perfusion and a high uteropla-
cental resistance, creating an environment of hypoxia to placental
and fetal tissues. Placental hypoxia results in the release of several
cytokines that, when exposed to the maternal circulation, are able
to alter the vascular response. This causes a widespread
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gested that pro-inﬂammatory cytokines such as interleukin (IL)-6
and tumour necrosis factor alpha (TNFa) may be important medi-
ators of ischemia in placental and renal dysfunction [6,7], being
part of the origin of clinical changes in PE [8]. It is known that
maternal vascular disorders have a direct consequence to the
development and growth of the placenta and fetus. This highlights
the importance of evaluating not only the maternal hypoxic
response, but also in combination with fetal and placental conse-
quences of hypoxia.
Endocan-1 is a soluble proteoglycan expressed speciﬁcally on
endothelial cells, originally named endothelial cell-speciﬁc mole-
cule 1 (ESM-1) and ﬁrst described in human lung tissue [9]. This
molecule has been studied both in experimental models [10,11],
suggesting it as a possible marker and predictor of many diseases
associated with the vascular endothelium; Endocan-1 may also
have a functional role in endothelium-dependent pathological dis-
orders [12].
Endocan-1 secretion has been reported to be induced in the
presence of TNFa and IL-1b. In contrast, TNFa-inducted secretion
of Endocan-1 was inhibited by interferon gamma (IFNc). This sug-
gests that Endocan-1 may have additional non-classical functions
during the inﬂammatory reaction, which may be under control of
various cytokines [9,12].
The majority of studies of Endocan-1 have been in tumours
[13–25]. However, in inﬂammatory conditions, increased serum
Endocan-1 concentration in septic shock [12] and sepsis [13,26–
29] as well as in association with hypertension and obesity
[30,31] have been reported [27]. We are not aware of evidence in
the literature other than two abstract publications [32,33] and
two original article [34,35] of detailed studies relating Endocan-1
with PE (one of them showing a upregulation of Endocan-1 in
maternal plasma in patients with PE at the end of pregnancy,
and another did not ﬁnd any difference between groups at the
same period), and none of them are combining maternal, fetal
plasma and placenta.
We thus hypothesised that Endocan-1 would be up regulated in
maternal plasma and placenta and down regulated in fetal plasma
in women with PE, contributing to the pro-inﬂammatory condi-
tions characteristic of this syndrome.
The aims of our study were to analyse the levels of Endocan-1 in
maternal and fetal plasma and placental tissue from women with
PE and normotensive (NT) pregnancy in the third trimester of their
pregnancy. We also correlated maternal and fetal (umbilical
venous) Endocan-1 concentrations with clinical variables in both
groups.2. Material and methods
This was an observational study of pregnant women 20 or more
weeks of gestation, carrying a single fetus, with or without a diag-
nosis of PE, who were hospitalised at São Lucas Hospital, Pontiﬁcal
Catholic University of Rio Grande do Sul (HSL/PUCRS), Porto Alegre,
Brazil, between 2010 and 2013. All samples were collected after
obtaining informed, written consent. The study was approved by
the institution Scientiﬁc and Ethics Research Committee (No.
11/05352-CEP). PE was deﬁned according to the National High
Blood Pressure Education Program [36] and to the VI Brazilian
Guidelines on Hypertension 2010 [37]: blood pressure P140/
90 mmHg, associated with pathological proteinuria P300 mg/
24 h or proteinuria/creatininuria ratio P0.3, after 20 weeks of
gestation.
Women were excluded if they had a previous diagnosis of kid-
ney disease, liver disease, active infection, multiple gestation and/
or lack of information in the database.2.1. Sample collection
Maternal blood collection of patients with PE and NT was per-
formed after diagnosis and hospitalisation. A total of 117 patients
were collected (50 with PE and 67 NT) and 74% of samples were
obtained with matched maternal and fetal plasma and placenta.
Before delivery, 4 ml of maternal blood was collected in
ethylenediamine tetraacetic acid (EDTA) tubes. Shortly after birth,
4 ml of blood was taken from the umbilical cord vein. The samples
were centrifuged at 2000 g for 10 min, stored in a 600 ll aliquots
ﬁrstly, at 20 C and then at 80 C until the time of analysis.
Placental tissue collection was performed immediately after
birth. Six cubes of approximately 1 cm3 from the centre of a central
cotyledon located at half the distance between the cord and the
placental edge were collected. This material was stored under
the same conditions as plasma, until the time of analysis.
The sitting blood pressure was measured. Routine laboratory
tests were measured at the clinical pathology laboratory from
HSL/PUCRS. Tests for the diagnosis of PE and tests of gravity were
quantiﬁed only in pregnant women with PE.2.2. Preparation of samples
Samples were prepared according to instructions of the
Milliplex assay kit – MagPlexTH-C assay supplier. Protease inhibitor
cocktail (Millipore Corporation) was added to placental tissue
(300 mg) and diluted in RIPA Lysis Buffer 10X concentration of
3 ml/g of tissue. In sequence, mechanic maceration of the placental
tissue followed by sonication in bath sonicator was made
(Aquasonic, Cortland, New York, USA) for 10 min in ice bath.
Material was centrifuged at 12,000g for 10 min at 4 C (Sanyo,
London, Great Britain), 200 ll of the supernatant was aliquoted
into 600 ll tubes and stored at 20 C until subsequent analysis.
The protein concentration of the solution was measured using
2.0 Qubit Fluorometer (Invitrogen Life Technologies), in mg/ml
and adjusted to mg/g depending on buffer concentration (3 ml/g).
To calculate the concentration of molecules in the study, a
MagPlexTH-C system – microspheres assay (MAGPIX System,
Luminex, Austin, Texas, USA), Kit milliplex HCVD1MAG-67K-02 –
(Millipore Corporation, Billerica, MA, USA) and Exponent software
(Xponent 4.2) were used. The intra-assay and inter-assay coefﬁ-
cient of variation was <10%. The linear correlation coefﬁcient (r)
of Endocan-1 standard curve, according to the Luminex instru-
ment, was r = 0.98.2.3. Statistical analysis
Statistical tests were performed using the Statistical Package for
Social Sciences version 19 (SPSS 19.0) for Windows, Graphpad
Prism 6 and WINPEPI program (PEPI-for-Windows). Quantitative
variables were presented as mean ± standard deviation (SD) or
median and interquartile range (IQR) as appropriate, Mann–
Whitney U-test and Student t test were used depending on the
data distribution. For categorical variables, we used percentage
and applied the chi-square test or Fisher’s exact test. Correlations
between parameters were tested with Pearson’s correlation coefﬁ-
cient. The data related to the dosage of Endocan-1 were analysed
by logarithmic transformation for Analysis of Covariance
(ANCOVA) adjusted for BMI, gestational age (GA) and maternal
age (presented as geometric mean). To estimate the proportion of
the difference of Endocan-1 between groups, the ratio of the mean
and conﬁdence interval of 95% were calculated. The magnitude of
the differences was estimated by Cohen’s effect size. The null
hypothesis was rejected when p < 0.05.
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Endocan-1 is one of the molecules that has recently been stud-
ied in relation to vascular and inﬂammatory diseases, and seems to
be dependent on others cytokines and endothelial growth factors.
Future work with the measurement of Endocan-1 in human ﬂuids
and the association with others vascular biomarker may be part of
the understanding of PE pathophysiology.3. Results
3.1. Study subjects
Clinical and demographic characteristics, physical examination
data, laboratory tests and data of delivery are presented in
Table 1. Physical examination data are relative to the day of
admission.3.2. Endocan-1
The median maternal plasma Endocan-1 concentration (ng/ml)
in women with PE was signiﬁcantly higher than NT group (2.86
[2.14, 4.68] vs. 1.80 [1.36, 2.51] p < 0.001). In contrast, placental
Endocan-1 levels (lg/g) were lower in PE group (1.52 [1.10, 2.40]
vs. 2.24 [1.32, 3.75], p = 0.033). Fetal Endocan-1 concentration
(ng/ml) did not show any difference between groups (3.10 [2.60,
4.54] vs. 2.91 [2.20, 3.66] p = 0.085), PE vs. NT, for all.
Data related to the dosage of Endocan-1 were analysed by
ANCOVA, adjusted for BMI, gestational age and maternal age, being
presented as geometric mean.
Endocan-1 geometric mean ratio in maternal plasma of women
with PE was higher compared to NT. The estimated magnitude by
Cohen’s effect size (d), applied in log measures obtained by
ANCOVA model, was 0.84 (moderate magnitude). There was no
statistical difference in fetal plasma and placental levels of
Endocan-1 between NT and PE groups. Based on the matched sam-
ples, we found a negative correlation between Endocan-1 inTable 1
Clinical data, maternal and fetal physical examination data, and laboratory tests from
NT and PE groups.
Parameters NT (67) PE (50) p
Maternal age (years) 26 ± 5 26 ± 6.8 0.10
Caucasians, n (%) 34 (52) 31 (65) 0.25
Primiparous, n (%) 28 (42) 25 (51) 0.35
Chronic hypertension, n (%) 0 (0) 12 (24.5) –
Previous PE, n (%) 1 (1.5) 12 (24.0) –
BMI (at the end of pregnancy) (kg/
m2)
30.4 ± 5.8 32.3 ± 5.4 0.081
Systolic blood pressure (mmHg) 119 ± 10 157 ± 17 <0.001
Diastolic blood pressure (mmHg) 75 ± 8 101 ± 14 <0.001
Gestational age at delivery (weeks) 39.6 ± 1.4 36.7 ± 3.7 <0.001
Cesarean delivery, n (%) 22 (32.8) 38 (76.0) <0.001
Apgar index in the ﬁrst minute, n 8.6 ± 0.8 7.54 ± 1.81 <0.001
Apgar index in the ﬁfth minute, n 9.4 ± 0.6 8.72 ± 1.21 <0.001
Birth weight (g) 3393 ± 458 2789 ± 904 <0.001
Placental weight (g) 649 ± 142 590 ± 179 0.063
Hematocrit (%) 35.2 ± 2.5 36.22 ± 3.51 0.14
Haemoglobin (g/dL) 11.6 ± 0.9 12.31 ± 1.28 0.004
Platelet count, 103 mm3 211.00 ± 59.05 –
Creatinine (mg/dL) 0.81 ± 0.21 –
Uric acid (mg/dL) 5.12 ± 1.5 –
Proteinuria, P/C ratio (median [IQR]) 0.67 [0.42,
2.2]
–
Fasting glucose (mg/dL) 75.2 ± 9.3 78.9 ± 13.7 0.26
NT: normotensive pregnant women. PE: pre-eclampsia. BMI: Body Mass Index. Data
are presented as mean ± SD (Student’s t-test), median [IQR] or in absolute numbers
and percentage [n (%) Fisher’s exact test], as appropriate.maternal and fetal plasma with birthweights (r = 0.42,
p < 0.001; r = 0.281, p = 0.004, respectively), placental weight
(r = 0.34, p = 0.001; r = 0.289, p = 0.003, respectively) and gesta-
tional age at delivery (r = 0.382, p < 0.001; r = 0.260, p = 0.008,
respectively). Regarding to maternal blood pressure levels analys-
ing all samples, we observed a positive correlation the levels of
Endocan-1 in maternal plasma with both systolic and diastolic
blood pressure (r = 0.40, p < 0.001; r = 0.462, p < 0.001, respec-
tively), in late pregnancy. We also veriﬁed correlations with mater-
nal plasma when we analysed the PE group separately, including,
gestational age at delivery (r = 0.411, p = 0.004), birthweight
(r = 0.376, p = 0.009), placental weight (r = 0.333, p = 0.026)
and BMI at the end of pregnancy (r = 0.387; p = 0.009). Finally,
we found the association between levels of Endocan-1 in maternal
plasma vs. fetal plasma (r = 0.258, p = 0.015). Fig. 1 shows the
result of the ANCOVA test presenting mean ratio between geomet-
ric means of Endocan-1 levels of PE and NT groups and also the
conﬁdence interval of Endocan-1 concentrations after logarithmic
transformation in maternal plasma, fetal plasma and placental
tissue.
After analysing PE compared to NT women, we chose to re-anal-
yse data excluding women with HELLP syndrome (Hemolysis,
Elevated Liver Enzymes, Low platelet Count) (n = 5) and patients
with prior chronic hypertension (n = 12). Endocan-1 concentra-
tions remained signiﬁcantly increased in PE maternal plasma, with
a magnitude by Cohen’s effect size (d) of 0.94 (moderate magni-
tude). We also opted to subdivide the PE group, creating three
groups, in relation to gestational age (34 and 37 weeks’), systolic
blood pressure (cut off at 160 mmHg) and proteinuria (cut off at
0.5 and 2.0) and compare these with NT women. A signiﬁcant
increase in maternal plasma Endocan-1 concentration in all PE
groups was also still observed (p < 0.001).4. Discussion
Our hypothesis was that Endocan-1 as an endothelial cell mar-
ker would be up regulated in maternal plasma and placenta and
down regulated in women with PE due to its well known role in
endothelial dysfunction characteristic in the pathogenesis of PE.
At the end of the study, we observed increased levels of
Endocan-1 in patients with PE in maternal blood plasma, which
in contrast to what was observed in the placenta.
Joost et al., reported Endocan-1 as a prognostic marker for the
development of early and severe PE [32], a ﬁnding similar to our
study. The results showed that between the 12th and 16th week
of pregnancy the concentration of Endocan-1 was reduced in
patients who later develop severe early-onset PE. On the other
hand, in the period between the 24th week of pregnancy and deliv-
ery, concentrations of Endocan-1 increased signiﬁcantly in patients
with severe early-onset PE and severe late-onset PE compared to
healthy pregnant women [32]. During pregnancy, levels of
Endocan-1 in maternal serum seems to be regulated with progres-
sion of gestational age, decreasing at term. However, in severe
early-onset PE an up-regulation of Endocan-1 is observed and sug-
gests an advanced degree of endothelial activation and injury in
early gestational age [33]. In our study, we have not analysed
Endocan-1 in early pregnancy. However based on these two previ-
ous preliminary studies, Endocan-1 seems to have an important
role in angiogenic process in the early- and mid-pregnancy, as well
as a pro-inﬂammatory role in late pregnancy. This may explains
this molecule involvement in PE during the whole pregnancy.
Recently Adekola et al. demonstrated that the median maternal
plasma Endocan-1 concentrations were higher in PE than in
uncomplicated pregnancies [34], also in agreement with our study.
In contrast, Yuksel et al. could not ﬁnd any difference of mean
Fig. 1. Endocan-1 levels in pre-eclamptic and normotensive groups. Gm_PE: geometric mean of patients with preeclampsia. Gm_NT: geometric mean of normotensive
pregnant women. MR: mean ratio. CI: conﬁdence interval.
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women. However, as our study, they found that mean Endocan-1
levels were negatively correlated with BMI at the time of blood
sampling, but questioning the possibility of Endocan-1 not being
directly related to PE [35].
It is known that cell injury occurs from early pregnancy, in
extracellular matrix and in the vessel wall of the maternal decidua
in order to create a favourable environment for the implantation of
the conceptus. Endocan-1 expression is regulated by cytokines,
suggesting that it may play a role in endothelium-dependent
pathological disorders [9]. Also, previous studies show its up-regu-
lation in the presence of vascular endothelial growth factor (VEGF),
which is known to be associated with PE. We believe that the sig-
niﬁcant increase of Endocan-1 in maternal plasma might be due to
a heightened physiological response to this developmental process,
together with the increased release of pro-inﬂammatory cytokines.
Moreover, placental ischemic injury due to improper remodelling
of decidual vessels, releases molecular mediators in the maternal
circulation and generates an imbalance between vasoconstrictors
and vasodilators contributing to the development of PE.
There is still a question in relation to why Endocan-1 seems to
be down regulated in placenta from women with PE. Adekola et al.,
studied Endocan-1 in women with pyelonephritis and observed
that the median plasma Endocan-1 concentration was lower in
pregnancies complicated by acute pyelonephritis induced inﬂam-
mation [34] showing that pyelonephritis might follow the same
inﬂammatory response as in observed in placenta. Also, it was
observed that in a large number of trauma patients with high risk
of acute lung injury, the levels of Endocan-1 was reduced [38]. As
an explanation, it is believed that Endocan-1 can inhibit leucocyte
recruitment in an attempt to protect organs and tissues affected by
inﬂammatory process, and might be increased in acute inﬂamma-
tory process, suggesting a protective role associated with this
protein.
Endocan-1 may be elevated in the third trimester in an attempt
to protect the system against the inﬂammation caused by PE,
which could explain why in early gestation, Endocan-1 seems to
be lower than towards term in women with PE. However, different
mechanisms appear to be occurring in placental tissue, where
Endocan-1 is down regulated. The up regulation on Endocan-1 in
maternal plasma from women with PE, in our study, seems not
be related to all forms of PE, as this result was found in all substrate
analysed.
Also, when we analysed the patients excluding those with
HELLP and chronic hypertension, although a smaller sample of
patients, a signiﬁcant difference was still observed. The same hap-
pened when we subdivided the PE group. This suggests that PE per
se results in the increased Endocan-1 concentrations.Thus, our study is ﬁrst one to analyse concomitantly maternal
plasma, fetal plasma and placenta in women with PE, demonstrat-
ing increased Endocan-1 in the third trimester of pregnancy in
maternal plasma, in pregnant women with varying degrees of PE
and with the potential changes associated with prematurity and
low birth weight, warranting further investigations to elucidate
speciﬁc roles.4.1. Conclusion
This study evaluated the presence of Endocan-1 molecule in
maternal plasma fetal plasma and placental tissues. In addition,
we compared the levels of this cytokine in patients with NT and
PE. Stratiﬁcations were made in the PE group to better understand
the possible inﬂuences that variables such as IG, blood pressure
and proteinuria could have on comparisons and correlations
between groups and cytokines. The fact that Endocan-1 have been
shown to be signiﬁcantly increased in maternal plasma for all the
strata of the PE group, with a considerable magnitude, makes it a
great candidate for use as a PE biomarker and should receive focus
in future studies.Acknowledgments
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